Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow, Hematology, Oncology, Cellular Therpay, Duke University School of Medicine 2007 - 2010
  • M.D., Shanghai Second Medical University (China) 1991
• 

  Duke Appointment History

  • Instructor Temporary in the Department of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2014 - 2015
• Research
• 

  Selected Grants

  • PHASE 2 STUDY OF POMALIDOMIDE WITH LOW-DOSE DEXAMETHASONE awarded by Celgene Corporation 2017 - 2022
  • Develop and Support of the RedCap database, bio-statistic analysis, and med writing for Dr Kang NIH SBIR award Clin Trial awarded by RedHill Biopharma Ltd. 2016 - 2021
  • Transfusion Medicine and Hematology awarded by National Institutes of Health 1975 - 2021
  • Clinical characteristics, JAK2 status, and macrophage infiltration in multiple myeloma patients with marrow fibrosis awarded by Incyte Corporation 2017 - 2020
  • Targeting sphingosine kinase 2 for the treatment of multiple myeloma awarded by National Institutes of Health 2015 - 2020
  • Ph III study to evaluate the safety of ALN-TTR02 in TTR-Medicated Polyneuropathy awarded by Alnylam Pharmaceuticals 2014 - 2019
  • Clinical Trial of ABC294640 in Patients with Refractory Multiple Myeloma awarded by Apogee Biotechnology Corporation 2015 - 2018
  • Thioredoxin for radioprotection awarded by Columbia University 2016 - 2018
  • Plerixafor for allogeneic hematopoietic stem cell transplantation awarded by National Institutes of Health 2014 - 2016
• Publications & Artistic Works
• 

  Selected Publications

  • Book Sections

    • Kang, Y, and Chao, NJ. "Strategies to enhance hematopoietic stem cell engraftment following transplantation." In Novel Developments in Stem Cell Mobilization: Focus on CXCR4, 439-456. January 1, 2012.  Full Text
    • Kang, Y, and Chao, N. "Immune reconstitution." In Hematopoietic Stem Cell Transplantation A Handbook for Clinicians, edited by JR Wingard, D Gastineau, H Leather, EC Snyder, and ZM Szczepiokowski, 181-196. Bethesda, MD: AABB Press, 2010. (Chapter)
    • Kang, Y, and Cheng, YB. "A Handbook of Human Cytokines." In Interleukin-3, edited by J He and DX Wang, 79-96. China: Tong Zi University Press, 1996. (Chapter)
    • Kang, Y, and He, J. "Interleukin-4." In A Handbook of Human Cytokines, edited by J He and DX Wang, 97-112. China: Tong Zi University Press, 1996. (Chapter)

  • Conference Papers

    • Sivaraj, D, Green, MM, Kang, Y, Rizzieri, D, Diehl, LF, Beaven, AW, Li, Z, Garrett, A, McIntyre, J, Long, GD, Chao, NJA, and Gasparetto, C. "Phase VII dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (BPd) in patients with relapsed/refractory multiple myeloma." May 20, 2017.  Full Text  Link to Item
    • Gasparetto, C, Green, M, Srinivasan, A, Kang, Y, Rizzieri, DA, Decastro, C, Diehl, LF, Beaven, A, Li, Z, Rao, AV, Garrett, A, Tuchman, S, and Long, GD. "A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma." December 3, 2015.  Link to Item
    • Green, MM, Horwitz, ME, Kang, Y, Chao, NJ, Long, GD, Rizzieri, D, Gasparetto, C, Sung, AD, Sarantopoulos, S, Li, Z, Corbet, K, Riggan-Stuelke, E, Sullivan, K, Wilson, B, Chhabra, S, Costa, LV, Mims, A, and Stuart, R. "Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial." February 2015.  Full Text
    • Zhou, D, Deoliveira, D, Kang, Y, Choi, SS, Chao, NJ, and Chen, BJ. "Insulin-Like Growth Factor 1 Mitigates Hematopoietic Toxicity After Lethal Total Body Irradiation." February 2013.  Full Text
    • An, N, Im, Y-B, Lin, Y, Gasparetto, C, Costa, LJ, Stuart, RK, Smith, C, Kraft, A, and Kang, Y. "Characterization of Pim Protein Kinases and Evaluation of Small Molecule Inhibitors in Multiple Myeloma." November 18, 2011.  Link to Item

  • Digital Publications

    • An, N, and Kang, Y. "In vivo BrdU Incorporation Assay for Murine Hematopioetic Stem Cells." (2013).  Link to Item

  • Journal Articles

    • Zheng, Z, Fan, S, Zheng, J, Huang, W, Gasparetto, C, Chao, NJ, Hu, J, and Kang, Y. "Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma." Journal of hematology & oncology 11, no. 1 (February 27, 2018): 29-.  Full Text
    • Kumar, SK, Callander, NS, Alsina, M, Atanackovic, D, Biermann, JS, Castillo, J, Chandler, JC, Costello, C, Faiman, M, Fung, HC, Godby, K, Hofmeister, C, Holmberg, L, Holstein, S, Huff, CA, Kang, Y, Kassim, A, Liedtke, M, Malek, E, Martin, T, Neppalli, VT, Omel, J, Raje, N, Singhal, S, Somlo, G, Stockerl-Goldstein, K, Weber, D, Yahalom, J, Kumar, R, and Shead, DA. "NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018." Journal of the National Comprehensive Cancer Network : JNCCN 16, no. 1 (January 2018): 11-20.  Full Text
    • Sivaraj, D, Bacon, W, Long, GD, Rizzieri, DA, Horwitz, ME, Sullivan, KM, Kang, Y, Li, Z, Chao, NJ, and Gasparetto, C. "High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma." Bone marrow transplantation 53, no. 1 (January 2018): 34-38.  Full Text
    • Sundaramoorthy, P, Wang, Q, Zheng, Z, Jiao, Y, Chen, BJ, Doan, PL, Chao, NJ, and Kang, Y. "Thioredoxin mitigates radiation-induced hematopoietic stem cell injury in mice." Stem cell research & therapy 8, no. 1 (November 15, 2017): 263-.  Full Text
    • Tuchman, SA, Moore, JO, DeCastro, CD, Li, Z, Sellars, E, Kang, Y, Long, G, and Gasparetto, CG. "Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma." Journal of geriatric oncology 8, no. 3 (May 2017): 165-169.  Full Text
    • Sivaraj, D, Green, MM, Li, Z, Sung, AD, Sarantopoulos, S, Kang, Y, Long, GD, Horwitz, ME, Lopez, RD, Sullivan, KM, Rizzieri, DA, Chao, NJ, and Gasparetto, C. "Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 23, no. 2 (February 2017): 262-268.  Full Text
    • Green, MMB, Chao, N, Chhabra, S, Corbet, K, Gasparetto, C, Horwitz, A, Li, Z, Venkata, JK, Long, G, Mims, A, Rizzieri, D, Sarantopoulos, S, Stuart, R, Sung, AD, Sullivan, KM, Costa, L, Horwitz, M, and Kang, Y. "Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery." Journal of hematology & oncology 9, no. 1 (August 17, 2016): 71-.  Full Text  Open Access Copy
    • An, N, Cen, B, Cai, H, Song, JH, Kraft, A, and Kang, Y. "Pim1 kinase regulates c-Kit gene translation." Experimental hematology & oncology 5 (January 2016): 31-.  Full Text
    • Schade, H, Chhabra, S, Kang, Y, Stuart, RK, Edwards, KH, Kramer, C, Butcher, C, Littleton, A, Schneider, M, Budisavljevic, MN, and Costa, LJ. "Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor." Transfusion 54, no. 12 (December 2014): 3131-3137.  Full Text
    • Venkata, JK, An, N, Stuart, R, Costa, LJ, Cai, H, Coker, W, Song, JH, Gibbs, K, Matson, T, Garrett-Mayer, E, Wan, Z, Ogretmen, B, Smith, C, and Kang, Y. "Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma." BLOOD 124, no. 12 (September 18, 2014): 1915-1925.  Full Text  Link to Item
    • Venkata, JK, An, N, Stuart, R, Costa, LJ, Cai, H, Coker, W, Song, JH, Gibbs, K, Matson, T, Garrett-Mayer, E, Wan, Z, Ogretmen, B, Smith, C, and Kang, Y. "Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma." Blood 124, no. 12 (September 2014): 1915-1925.  Full Text
    • Costa, LJ, Nista, EJ, Buadi, FK, Lacy, MQ, Dispenzieri, A, Kramer, CP, Edwards, KH, Kang, Y, Gertz, MA, Stuart, RK, and Kumar, S. "Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification." Biology of Blood and Marrow Transplantation 20, no. 2 (February 2014): 222-228.  Full Text
    • An, N, and Kang, Y. "Thioredoxin and hematologic malignancies." Advances in cancer research 122 (January 2014): 245-279.  Full Text
    • Roof, L, Coker, WJ, Lazarchick, J, and Kang, Y. "Senile transthyretin cardiac amyloidosis in patients with plasma cell dyscrasias: importance of cardiac biopsy for making the correct diagnosis." Aperito journal of cellular and molecular biology 1, no. 1 (January 2014).
    • An, N, Janech, MG, Bland, AM, Lazarchick, J, Arthur, JM, and Kang, Y. "Proteomic analysis of murine bone marrow niche microenvironment identifies thioredoxin as a novel agent for radioprotection and for enhancing donor cell reconstitution." Experimental Hematology 41, no. 11 (November 2013): 944-956.  Full Text
    • An, N, Lin, Y-W, Mahajan, S, Kellner, JN, Wang, Y, Li, Z, Kraft, AS, and Kang, Y. "Pim1 Serine/Threonine Kinase Regulates the Number and Functions of Murine Hematopoietic Stem Cells." STEM CELLS 31, no. 6 (June 2013): 1202-1212.  Full Text
    • Zhou, D, Deoliveira, D, Kang, Y, Choi, SS, Li, Z, Chao, NJ, and Chen, BJ. "Insulin-like growth factor 1 mitigates hematopoietic toxicity after lethal total body irradiation." Int J Radiat Oncol Biol Phys 85, no. 4 (March 15, 2013): 1141-1148.  Full Text  Link to Item
    • An, N, Kraft, AS, and Kang, Y. "Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice." Journal of Hematology & Oncology 6, no. 1 (2013): 12-12.  Full Text
    • An, N, and Kang, Y. "Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model." Journal of Visualized Experiments , no. 73 (2013).  Full Text
    • Coker, WJ, Jeter, A, Schade, H, and Kang, Y. "Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms." Biomarker Research 1, no. 1 (2013): 8-8.  Full Text
    • Kellner, J, Liu, B, Kang, Y, and Li, Z. "Fact or fiction - identifying the elusive multiple myeloma stem cell." Journal of Hematology & Oncology 6, no. 1 (2013): 91-91.  Full Text
    • Butler, C, Wolff, DJ, Kang, Y, Stuart, RK, and Costa, LJ. "Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients." Leukemia & Lymphoma 53, no. 12 (December 2012): 2444-2448.  Full Text
    • Costa, LJ, Abbas, J, Hogan, KR, Kramer, C, McDonald, K, Butcher, CD, Littleton, A, Shoptaw, K, Kang, Y, and Stuart, RK. "Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure." Bone Marrow Transplantation 47, no. 11 (November 2012): 1403-1408.  Full Text
    • Costa, LJ, Abbas, J, Ortiz-Cruz, KL, Kang, Y, and Stuart, RK. "Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange." European Journal of Haematology 89, no. 5 (November 2012): 432-434.  Full Text
    • Costa, LJ, Kramer, C, Hogan, KR, Butcher, CD, Littleton, AL, Shoptaw, KB, Kang, Y, and Stuart, RK. "Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis." Transfusion 52, no. 11 (November 2012): 2375-2381.  Full Text
    • Jeter, A, and Kang, Y. "Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy." Experimental Hematology & Oncology 1, no. 1 (2012): 20-20.  Full Text
    • Kang, Y, Chen, BJ, Deoliveira, D, Mito, J, and Chao, NJ. "Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model." PLoS ONE 5, no. 6 (2010).  Full Text  Open Access Copy
    • Kang, Y, Chao, NJ, and Aversa, F. "Unmanipulated or CD34 selected haplotype mismatched transplants." Current Opinion in Hematology 15, no. 6 (2008): 561-567.  Full Text
    • Kang, Y, Moressi, CJ, Scheetz, TE, Xie, L, Tran, DT, Casavant, TL, Ak, P, Benham, CJ, Davidson, BL, and McCray, PB. "Integration Site Choice of a Feline Immunodeficiency Virus Vector." Journal of Virology 80, no. 17 (September 1, 2006): 8820-8823.  Full Text
    • Kang, Y. "Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer." Blood 106, no. 5 (September 1, 2005): 1552-1558.  Full Text
    • Song, L, Wang, J, Wang, R, Yu, M, Sun, Y, Han, G, Li, Y, Qian, J, Scott, D, Kang, Y, Soukhareva, N, and Shen, B. "Retroviral delivery of GAD-IgG fusion construct induces tolerance and modulates diabetes: a role for CD4+ regulatory T cells and TGF-β?." Gene Therapy 11, no. 20 (October 2004): 1487-1496.  Full Text
    • Starner, TD, Barker, CK, Jia, HP, Kang, Y, and McCray, PB. "CCL20 Is an Inducible Product of Human Airway Epithelia with Innate Immune Properties." American Journal of Respiratory Cell and Molecular Biology 29, no. 5 (November 2003): 627-633.  Full Text
    • Kang, Y, Stein, CS, Heth, JA, Sinn, PL, Penisten, AK, Staber, PD, Ratliff, KL, Shen, H, Barker, CK, Martins, I, Sharkey, CM, Sanders, DA, McCray, PB, and Davidson, BL. "In Vivo Gene Transfer Using a Nonprimate Lentiviral Vector Pseudotyped with Ross River Virus Glycoproteins." Journal of Virology 76, no. 18 (September 15, 2002): 9378-9388.  Full Text
    • Melo, MEF, Qian, J, El-Amine, M, Soukhareva, N, Kang, Y, and Scott, DW. "Gene transfer of immunoglobulin-fusion proteins prevents and treats autoimmune diseases." J. Immunol 168, no. 9 (2002): 4788-4795.
    • Stein, CS, Kang, Y, Sauter, SL, Townsend, K, Staber, P, Derken, TA, Martins, I, Qian, J, Davidson, BL, and McCray, PB. "In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using non-primate lentiviral vectors." Molecular Therapy 3 (2001): 850-856.
    • Agarwal, RK, Kang, Y, Zambidis, E, Scott, DW, Chan, C-C, and Caspi, RR. "Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis." Journal of Clinical Investigation 106, no. 2 (July 15, 2000): 245-252.  Full Text
    • El-Amine, M, Melo, MEF, Kang, Y, Qian, J, and Scott, DW. "Mechanisms of tolerance induction by an Ig-peptide molecule expressed and secreted by B cells." Journal of immunology (Baltimore, Md. : 1950) 165 (2000): 5631-5636.
    • Kang, Y, Melo, M, Deng, E, Tisch, R, El-Amine, M, and Scott, DW. "Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: The IgG scaffold is important for induction and maintenance of immune hyporesponsiveness." Proceedings of the National Academy of Sciences 96, no. 15 (July 20, 1999): 8609-8614.  Full Text
    • Kang, Y, Melo, MEF, and Scott, DW. "An Ongoing Immune Response to HIV Envelope gp120 in Human CD4 Transgenic Mice Contributes to T Cell Decline upon Intravenous Administration of gp120." European Journal of Immunology 28 (1998): 2253-2264.
    • Kang, Y, Edwards, LG, and Thornalley, PJ. "Effect of methylglyoxal on human leukaemia 60 cell growth: Modification of DNA, G1 growth arrest and induction of apoptosis." Leukemia Research 20, no. 5 (May 1996): 397-405.  Full Text
    • Thornalley, PJ, Edwards, L, Kang, Y, Wyatt, C, Davies, N, Ladan, MJ, and Double, J. "Anti-tumor Activity of S- (p-bromobenzyl)glutathione Cyclopentyl Diesters In Vitro and In Vivo: Inhibition of Glyoxalase I and Induction of Apoptosis." Biochemical Pharmacology 51, no. 10 (1996): 1365-1372.
    • Thornalley, PJ, Ladan, M, Ridgeway, S, and Kang, Y. "Anti-tumor Activity of S-(p-bromobenzyl)glutathione Diesters in vitro: a Structure-Activity Study." Journal of Medicinal Chemistry 39, no. 17 (1996): 3409-3411.
    • Huang, LA, Cheng, QS, Kang, Y, and Li, YH. "Cytomegalovirus Infection in Bone Marrow Transplant Patients with Acute Radiation Sickness." Edited by BT Liu and GY Ye. (1994): 315-319.
    • Huang, LA, Meng, PL, Kang, Y, Cheng, QS, and Liu, BT. "Clinical Observation and Prevention of Coagulation Abnormality in 7 Cases of Patients with Acute Radiation Sickness." Edited by BT Liu and GY Ye. (1994): 348-356.
    • Kang, Y, Gu, CN, Meng, PL, Cao, LX, and Huang, LA. "Monitoring of Blood Cyclosporine A Concentration and Clinical Observation in Patients with HLA-semimatched Bone Marrow Transplantation." Edited by BT Liu and GY Ye. (1994): 402-409.
    • Kang, Y, Zing, SW, Meng, PL, Cao, LX, and Huang, LA. "Capillary Leakage Syndrome Associated with Acute Radiation Disease." Edited by BT Liu and GY Ye. (1994): 311-314.
    • Kang, Y, Yu, RQ, and Kong, XT. "Tumor Cell Surface Markers and Differentiation on Multiple Myeloma." Chinese Journal of Hematology 7 (1992): 384-387. (Review)
    • Kang, Y, and Yu, RQ. "Hypertension Associated with Cyclosporine A Treatment in Bone Marrow Transplantation." Foreign Medicine (Blood Transfusion & Hematology) 5 (1991): 288-291. (Review)
    • Kang, Y, and Yu, RQ. "Therapeutic Progress in Multiple Myeloma." Foreign Medicine (Blood Transfusion & Hematology) 3 (1990): 140-143. (Review)

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.